Clinical Trial Update: Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rituximab with or without bleomycin sulfate for primary mediastinal large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Bleomycin sulfate (Bleomycin sulfate)
• Rituximab (rituximab)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN